Inventor · disambiguated record
Zhanggui Wu
Also filed as: WU ZHANGGUI
9 granted patents·3 pending applications·17 citations·filing 2006–2021
82Inventor score
Files withWU ZHANGGUI7SHANGHAI HUAYU BIOTECHNOLOGY CO LTD2SHANGHAI HUAYU BIOTECHNOLOGY CO LTS1ZHEJIANG JIANFENG YIEN BIOTECHNOLOGY CO LTD1ZHEJIANG MED XINCHANG PHARM1
Top patents by PatentIndex Score
12 records- 0181US8318740B2Compounds for protein kinase inhibitionWU ZHANGGUI·Filed 2009·Granted Nov 27, 2012·6 cites·17 claims
- 0278US7399754B2N2-quinoline or isoquinoline substituted purine derivativesWU ZHANGGUI·Filed 2006·Granted Jul 15, 2008·3 cites·24 claims
- 0377US8962626B2Thienopyridazine compounds, their preparations, pharmaceutical compositions and usesWU ZHANGGUI·Filed 2009·Granted Feb 24, 2015·3 cites·7 claims
- 0473US8815863B2Compounds and therapeutic use thereof for protein kinase inhibitionWU ZHANGGUI·Filed 2010·Granted Aug 26, 2014·3 cites·5 claims
- 0567US9487539B2Compounds and therapeutic use thereof for protein kinase inhibitionWU ZHANGGUI·Filed 2014·Granted Nov 8, 2016·1 cites·11 claims
- 0667US9249154B2Compounds and therapeutic use thereof for protein kinase inhibitionWU ZHANGGUI·Filed 2012·Granted Feb 2, 2016·1 cites·17 claims
- 0759US2023049029A1Combination cancer therapy using chk inhibitorSHANGHAI HUAYU BIOTECHNOLOGY CO LTS·Filed 2021·Application pending·0 cites
- 0852US2023201207A1Combination cancer therapy using n2-quinoline or isoquinoline substituted purine derivativesSHANGHAI HUAYU BIOTECHNOLOGY CO LTD·Filed 2021·Application pending·0 cites
- 0950US2023087844A1Use of n2-quincline or isoquinoline substituted purine derivatives in cancer treatmentSHANGHAI HUAYU BIOTECHNOLOGY CO LTD·Filed 2021·Application pending·0 cites
- 1044US8580763B22, 6-dinitrogen-containing substituted purine derivatives, the preparation and uses thereofWU ZHANGGUI·Filed 2008·Granted Nov 12, 2013·0 cites·18 claims
- 1139US9718823B22, 6-Di-nitrogen-containing substituted purine derivative, and preparation method, pharmaceutical composition and use thereofZHEJIANG MED XINCHANG PHARM·Filed 2014·Granted Aug 1, 2017·0 cites·12 claims
- 1232US10844074B2Heterocycle compounds and uses thereofZHEJIANG JIANFENG YIEN BIOTECHNOLOGY CO LTD·Filed 2016·Granted Nov 24, 2020·0 cites·28 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →